Last reviewed · How we verify

NCT04793490

Sphenopalatine Ganglion Block for Management of Post- Dural Puncture Headache in Obstetric Patients

Completed NA Last updated 16 February 2022
What this trial tests

NA trial testing Sphenopalatine ganglion block in Post-Dural Puncture Headache in 40 participants. Completed in 5 December 2021.

Timeline
15 March 2021
Primary endpoint
25 November 2021
5 December 2021

Quick facts

Lead sponsorAin Shams University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment40
Start date15 March 2021
Primary completion25 November 2021
Estimated completion5 December 2021
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Ain Shams University

Who can join

Adults 21 to 45, female only, with Post-Dural Puncture Headache. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this trial is to study the efficacy and efficiency of sphenopalatine ganglion block for management of post dural puncture headache in obstetric patients

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Sphenopalatine ganglion block

Trials testing the same drug.

Other recruiting trials for Post-Dural Puncture Headache

Currently open trials in the same condition.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04793490.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing